血管新素II型2受体减弱了与衰老相关的动脉硬性在雌性小鼠
Casey G Turner1, Rachel Kenney1, Jennifer Vorn1
1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, United States.
概括
血管激素II型2受体 (AT2R) 能防止动脉硬化,特别是在老年女性中. 这项研究揭示了涉及AT2R在血管衰老中的性别特异机制.
科学领域:
- 心血管生理学心血管生理学
- 衰老研究研究 衰老研究
- 分子生物学分子生物学
背景情况:
- 动脉硬会增加死亡风险,特别是在55岁以上的女性中.
- 血管激素II型2受体 (AT2R) 可能会防止动脉硬化.
- 在女性心血管健康中,AT2R的作用比男性更为显著.
研究的目的:
- 调查AT2R在与衰老相关的动脉硬性性别差异中的作用.
- 探索AT2R在血管衰老中的功能背后的分子机制.
主要方法:
- 在老年雄性和雌性小鼠中研究了动脉硬性和AT2RmRNA表达.
- 在年轻和中年老鼠体内利用AT2R抑制.
- 分析了大动脉基因表达,包括整合蛋白α5和原1α1.1.
主要成果:
- 老龄化的女性显示出大动脉AT2RmRNA表达的时间损失,与男性不同.
- 慢性AT2R抑制增加了年轻女性和男性以及中年女性的动脉硬化.
- 在年轻男性中,AT2R抑制与整合蛋白α5的增加以及中年女性的原1α1相关.
结论:
- 在女性中确定了与衰老相关的动脉硬的性别特异性机制,涉及AT2R减弱和原上调.
- 在年轻的两性小鼠和中年雌性小鼠中证明了AT2R对动脉硬性的保护作用.
- 突出性别特定的分子通路,有助于AT2R在血管衰老中的作用.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
931
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
931
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
893
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
893
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
516
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516
Hypertension II: Pathophysiology
90
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
90
Antihypertensive Drugs: Direct Renin Inhibitors
835
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
835


